Assessment of fampridine-PR in NMO
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Dalfampridine
Voltage-gated potassium channel blocker
What it measured
Main measures
The primary outcome is the proportion of patients with consistent improvement in walking speed on the Timed 25ft walk during the treatment period (2)compared to Timed 25ft walk off treatment.
Disability progressionWalking and mobility
Other measures (1)
The secondary outcome is the proportion of patients with consistent improvement in their visual acuity, and colour vision as assessed by snellen and Ishihara will be completed.
Vision
Who could take part
NMOSD
Inclusion: Inclusion Criteria: Exclusion: Exclusion Criteria:
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Does Fampridine-PR improve walking speed in a group of patients with ambulatory deficits due to Neuromyelitis Optica (NMO)?
Loading reviews and guidelines…
Related trials
- Safety and Efficacy of Sustained Release Dalfampridine in…
Phase 2 · Completed
Results posted, no main test reported
History
Started
Oct 2013
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error